Geode Capital Management
CCCC icon

Geode Capital Management’s C4 Therapeutics CCCC Stock Holding History

Geode Capital Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.8M Buy
2,522,163
+1,571,120
+165% +$5.37M ﹤0.01% 2448
2026
Q1 		$2.5M Sell
951,043
-37,835
-4% -$89.1K ﹤0.01% 3043
2025
Q4 		$1.89M Buy
988,878
+263,574
+36% +$624K ﹤0.01% 3189
2025
Q3 		$1.61M Sell
725,304
-19,749
-3% -$47.4K ﹤0.01% 3256
2025
Q2 		$1.07M Sell
745,053
-685,235
-48% -$997K ﹤0.01% 3305
2025
Q1 		$2.29M Buy
1,430,288
+49,202
+4% +$147K ﹤0.01% 2988
2024
Q4 		$4.97M Buy
1,381,086
+11,410
+0.8% +$56.7K ﹤0.01% 2751
2024
Q3 		$7.81M Buy
1,369,676
+7,460
+0.5% +$44.9K ﹤0.01% 2513
2024
Q2 		$6.29M Buy
1,362,216
+851,901
+167% +$5.08M ﹤0.01% 2599
2024
Q1 		$4.17M Buy
510,315
+28,027
+6% +$217K ﹤0.01% 2795
2023
Q4 		$2.73M Buy
482,288
+26,444
+6% +$60.3K ﹤0.01% 2989
2023
Q3 		$848K Buy
455,844
+16,885
+4% +$51.5K ﹤0.01% 3396
2023
Q2 		$1.21M Sell
438,959
-401,819
-48% -$1.29M ﹤0.01% 3273
2023
Q1 		$2.64M Buy
840,778
+43,486
+5% +$256K ﹤0.01% 2916
2022
Q4 		$4.7M Buy
797,292
+20,070
+3% +$166K ﹤0.01% 2700
2022
Q3 		$6.82M Buy
777,222
+55,797
+8% +$579K ﹤0.01% 2493
2022
Q2 		$5.44M Buy
721,425
+53,606
+8% +$472K ﹤0.01% 2659
2022
Q1 		$16.2M Sell
667,819
-18,357
-3% -$446K ﹤0.01% 2027
2021
Q4 		$22.1M Buy
686,176
+19,853
+3% +$785K ﹤0.01% 1893
2021
Q3 		$29.8M Buy
666,323
+215,781
+48% +$9.24M ﹤0.01% 1699
2021
Q2 		$17M Buy
450,542
+257,950
+134% +$9.24M ﹤0.01% 2080
2021
Q1 		$7.12M Buy
192,592
+3,341
+2% +$133K ﹤0.01% 2593
2020
Q4 		$6.27M Buy
+189,251
New +$5.49M ﹤0.01% 2476

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management's CCCC Position: Q2 2026 in Review

Geode Capital Management increased its C4 Therapeutics (CCCC) stake by 165% in Q2 2026, buying an estimated $5.37M and bringing the position to 2,522,163 shares worth $11.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2448.

Geode Capital Management first reported a position in CCCC in Q4 2020 and has held it in 23 quarters since. The position peaked at $29.8M in Q3 2021. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Geode Capital Management held 2,522,163 shares of C4 Therapeutics worth $11.8M as of Q2 2026.
  • Geode Capital Management bought 1,571,120 C4 Therapeutics shares in Q2 2026, an estimated $5.37M.
  • C4 Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2448 holding.
  • Geode Capital Management first reported a position in C4 Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • Geode Capital Management's C4 Therapeutics position peaked at $29.8M in Q3 2021.
  • 148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.